一、历史回顾本世纪初Ehrlich 首先提出抗体具有作为药物载体的潜在用途,此种抗体特异地识别靶组织上的抗原,使交联在抗体上的药物理想地进入这些组织,而不进入其它不具有这种抗原的组织。这种药物传递系统最适合于低治疗指数的药物。现今使用的多数抗癌剂其治疗指数均低,且具有潜在的致命副作用。40年代发现了肿瘤细胞表面相关抗原(TAA),从而使应用肿瘤特异抗体作为药物 I. Historical Review Earlier this century, Ehrlich first proposed the potential use of antibodies as drug carriers that specifically recognize antigens on target tissues so that the drugs cross-linked to the antibody ideally enter these tissues without entering the other Tissues with this antigen. This drug delivery system is best suited for drugs with a low therapeutic index. Most anti-cancer agents used today have low therapeutic indices and potentially fatal side effects. The discovery of tumor cell surface antigen (TAA) in the 1940s led to the use of tumor-specific antibodies as drugs